Daye is a London‑based femtech company that builds period‑care and gynecological‑health products and services, combining sustainable consumer products (tampons, pads, subscription delivery) with at‑home diagnostics and clinical services aimed at closing the gender health gap.[1][5]
High‑Level Overview
- Concise summary: Daye is a consumer health and femtech company that makes sustainable period‑care products and develops at‑home gynae diagnostics and related services, delivered primarily direct‑to‑consumer via subscriptions and e‑commerce.[1][4][5]
- Product focus: organic and sustainable tampons and pads (including a pain‑relieving tampon in early product generations), vaginal probiotics and at‑home diagnostic kits for infections, STI/HPV detection and related gynae health monitoring.[1][2][4][5]
- Who it serves: people who menstruate (women and AFAB — assigned female at birth — individuals) seeking better period pain relief, infection screening and more proactive vaginal/menstrual health care.[2][5]
- Problem it solves: addresses unmet needs in menstrual pain management, access to gynae diagnostics outside traditional clinics, and lack of female‑focused medical research/products by delivering consumer‑friendly products and telehealth/diagnostic pathways.[2][5]
- Growth momentum: founded in 2017, Daye progressed from its initial product innovation (pain‑relief tampon) to a broader product and service set and raised venture funding (Series A / ~ $11.5M reported round), serving tens of thousands of customers via subscriptions and publicly stated user counts and research initiatives.[1][2][4]
Origin Story
- Founding year and team background: Daye was founded in 2017 in London; the company is female‑founded and lists a founder/CEO, CTO and medically trained research leads on its team, positioning itself at the intersection of clinical research and consumer product design.[1][5]
- How the idea emerged: the company started with the invention of a tampon designed to relieve menstrual cramp pain; subsequent product and research pathways expanded toward at‑home diagnostics and other gynae health conditions after early consumer traction and clinical interest.[2][5]
- Early traction / pivotal moments: Daye reports having helped over 75,000 people with its initial pain‑relieving product and later launched a second‑generation tampon platform enabling at‑home detection of vaginal infections, STIs and HPV, marking a shift from single product DTC to a combined product + diagnostic femtech approach.[2][5]
Core Differentiators
- Product differentiators: combines sustainable, organic period‑care products with clinically informed product features (e.g., pain relief formulation) and integration of diagnostics into a tampon‑based delivery platform.[1][2][5]
- Developer / clinical experience: salaried medical researchers and a resident doctor on the team signal internal clinical capability and research output accessible to consumers via the company blog and “Vitals” content.[5]
- Speed / convenience: subscription model and DTC distribution that aims to make period care and screening convenient and private compared with clinic‑based care.[4][5]
- Transparency & sustainability: publicly emphasizes supply‑chain transparency, sustainability framed holistically (environment, company wellbeing) and accessible science communication to bridge the gender research gap.[5]
- Community & growth: early user base (tens of thousands served) and recurring subscription revenue model support customer lifetime value and product iteration.[2][4]
Role in the Broader Tech Landscape
- Trend alignment: Daye is part of the broader femtech and consumer diagnostic trend — combining consumer goods, at‑home testing and digital health to decentralize sexual and reproductive healthcare.[2][5]
- Why timing matters: rising consumer acceptance of at‑home diagnostics, growing investment in women’s health, and demand for sustainable personal care products create favorable market forces for firms that integrate product, data and clinical pathways.[1][2]
- Market forces working in their favor: increased venture interest and public awareness of female‑specific health gaps, regulatory pathways maturing for home tests, and subscription DTC economics supporting customer acquisition and recurring revenue.[1][2]
- Influence on ecosystem: by publicly publishing research and building product–diagnostic combinations, Daye pushes other consumer health brands toward clinical validation and into gynae diagnostic innovation, while also increasing consumer expectations for privacy, transparency and clinical rigor in femtech.[5]
Quick Take & Future Outlook
- What's next: continued product‑platform expansion (broader diagnostics, services for conditions like endometriosis/PCOS/menopause as stated company goals), deeper clinical validation, and scaling subscriptions and telehealth integration.[2][5]
- Trends that will shape the journey: regulatory clarity for at‑home tests, reimbursement/telehealth integration, competition from established personal‑care brands entering femtech, and consumer demand for evidence‑based products.
- How influence might evolve: if Daye successfully validates diagnostic accuracy and builds clinical pathways, it could become a reference femtech brand that moves more gynae care from clinics to consumer platforms and influences regulatory and research priorities in women’s health.[2][5]
Quick take: Daye has positioned itself as a product‑led femtech company that pairs sustainable period care with clinically oriented at‑home diagnostics — that combination is its core differentiator and the lever that could determine whether it scales into a broader women’s health platform or remains a differentiated DTC care brand.[1][2][5]
Sources: Company profile and funding data from CB Insights and ZoomInfo, public company content and team/mission details from Daye’s About page and company statements.[1][4][5]
